A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study

INTRODUCTION: The search for drugs to treat Alzheimer's disease (AD) has failed to yield effective therapies. Here we report the first genome‐wide search for biomarkers associated with therapeutic response in AD. Blarcamesine (ANAVEX2‐73), a selective sigma‐1 receptor (SIGMAR1) agonist, was stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hampel, Harald, Williams, Coralie, Etcheto, Adrien, Goodsaid, Federico, Parmentier, Frédéric, Sallantin, Jean, Kaufmann, Walter E., Missling, Christopher U., Afshar, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167374/
https://www.ncbi.nlm.nih.gov/pubmed/32318621
http://dx.doi.org/10.1002/trc2.12013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167374/
https://www.ncbi.nlm.nih.gov/pubmed/32318621
http://dx.doi.org/10.1002/trc2.12013

Ejemplares similares